 | Up a level |
Journal Article
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Goto, K., Wolf, J., Elamin, Y., Santini, F., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B., Novello, S., Arriola Aperribay, E., Perol, M., Loong, H., Drilon, A., Park, K., Solomon, B. and Zhou, C. (2021). LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 16 (3). S. S228 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loong, H. H. F., Goto, K., Elamin, Y. Y., Solomon, B., Santini, F. C., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B. K., Wolf, J., Oxnard, G. R., Zhou, C., Drilon, A. and Park, K. (2020). LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC). Ann. Oncol., 31. S. S893 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Souquet, P-J., Kim, S-W., Solomon, B., Vansteenkiste, J. F., Carbini, M., Jary, A., Glaser, S., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study. Ann. Oncol., 32. S. S1033 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Planchard, D., Heist, R. S., Solomon, B., Sebastian, M., Santoro, A., Reguart, N., Stammberger, U., Manganelli, L., Wu, H., Mais, A. and Dooms, C. (2020). Phase Ib study of LXH254+LTT462 in patients with KRAS- or BRAF-mutant NSCLC. Ann. Oncol., 31. S. S881 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041